MAY 24, 2019 4:11 PM PDT

First PI3K Inhibitor for Breast Cancer

WRITTEN BY: Nouran Amin

The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.

“Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient’s specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

“For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks.”

It’s important to note that metastatic breast cancer is breast cancer that has reached to other organs in the body most notably the bones, lungs, liver or brain. When breast cancer is hormone-receptor-positive, patients receive anti-hormonal endocrine therapy either alone or in combination with other medicines.

Piqray is a Trademark of the biopharmaceutical company, Novartis

With the efficacy of Piqray and fulvestrant, it can significantly prolong progression-free survival in patients whose tumors had PIK3CA mutation.

Some common side-effects of Piqray include high blood glucose levels, an increase in creatinine, diarrhea, rash, decrease in white blood cell count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in pancreatic enzymes, decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, and hair loss.

Source: FDA

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 19, 2022
Drug Discovery & Development
Repurposing an Alcoholism Drug to Treat Anxiety
APR 19, 2022
Repurposing an Alcoholism Drug to Treat Anxiety
Anxiety is the most common mental illness in the U.S. According to the National Institutes of Health, nearly a third of ...
APR 21, 2022
Health & Medicine
Inhibiting a Key Signaling Pathway in Immune Cells Slows Alzheimer's Progression
APR 21, 2022
Inhibiting a Key Signaling Pathway in Immune Cells Slows Alzheimer's Progression
Weill Cornell Medicine researchers recently discovered that inhibiting a key signaling pathway in brain cells can lessen ...
APR 26, 2022
Immunology
Unraveling the Mystery of an Immune Cell Checkpoint
APR 26, 2022
Unraveling the Mystery of an Immune Cell Checkpoint
The immune system can get tired when it has to fight against a chronic infection or a disease like cancer. Exhausted T c ...
MAY 13, 2022
Drug Discovery & Development
Promising New Treatment for Cat Litter Parasite T. Gondii
MAY 13, 2022
Promising New Treatment for Cat Litter Parasite T. Gondii
Researchers have discovered a promising therapy for those suffering from toxoplasmosis, a disease caused by a parasite l ...
JUN 17, 2022
Cannabis Sciences
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
JUN 17, 2022
Projected Increases in Cannabis Use in States Legalizing Recreational Cannabis
A study published in the scientific journal Addiction found that people will be more likely to use cannabis as their sta ...
JUN 19, 2022
Drug Discovery & Development
Math Model Predicts Anti-inflammatory Drug Efficacy Post-heart Attack
JUN 19, 2022
Math Model Predicts Anti-inflammatory Drug Efficacy Post-heart Attack
Researchers created a mathematical model that can predict drug combinations that may one day help treat heart attacks. T ...
Loading Comments...